MOESM5 of Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR) FuchigamiAyako ShigiyamaFumika KitazawaToru OkadaYosuke IchijoTakamasa HigaMariko HiyoshiToru InoueIkuo IsoKaoru YoshiiHidenori HiroseTakahisa KumashiroNaoki 2020 Additional file 5: Table S4. Adverse events.